Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

ported an increased level of

genital arousal, an increased level of sexual desire and a higher

incidence of engaging in sexual activity compared to placebo.

-- The announcement of results from two Phase 2B trials evaluating

bremelanotide for ED, with one trial limited to non-diabetic patients

and the other to diabetic patients. The primary objective of the

studies was to characterize the efficacy and safety of bremelanotide in

these two ED populations and to identify the doses to use in further

development.

-- The completion of an exclusive global licensing and research

collaboration agreement with AstraZeneca AB to discover, develop and

commercialize small molecule compounds that target melanocortin

receptors for the treatment of obesity, diabetes and related metabolic

syndrome and the receipt of an up-front payment of $10 million.

-- The February 2007 sale of 13.75 million shares of its common stock in

an underwritten offering at $2.00 per share, resulting in net proceeds

to the Company of $25.5 million, after commissions and expenses.

-- The announcement in August 2007 of a delay in plans for the initiation

of Phase 3 clinical trials with bremelanotide for the treatment of ED

as a result of responses from representatives of the U.S. Food and Drug

Administration, which raised serious concerns about the acceptable

benefit/risk ratio to support the progression of bremelanotide into

Phase 3 studies for ED as a first-line therapy in the general

population.

-- The pending termination of the Collaborative Development and Marketing

Agreement with King, effective December 2007, upon which Palatin will

reacquire sole ownership of all rights to bremelanotide, without any

obligation for future payments to King. King has no financial

obligati
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer ... to be found at the junctures where ... burgeoning world of nanotechnology, the interfaces between ... prominent, with applications in such high-tech favorites ... Realizing the vast potential of these metal ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as ... its SBIR Phase 2 award from the Army ... comprehensive air purification system that kills all biological ... allergens and organic particulates.  In independent testing sponsored ...
(Date:1/15/2014)... and SAN JOSE, California , ... an international biotechnology company developing antibody-drug conjugates for cancer, ... PhD to its Board of Directors. Dr Reynolds has ... industry, most recently as Chief Medical Officer at Seattle ... at this transformative time for Oxford BioTherapeutics, as the ...
(Date:1/15/2014)... January 15, 2014 A study ... win races on the Formula 1 track could help ... collaboration between McLaren Applied Technologies (MAT), Stowhealth (a GP ... Suffolk is being funded by healthcare provider Simplyhealth. ... to collect data about the on-track performance of Vodafone ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... and Case Volumes Increase 53% and 52% Respectively ... ... Clarient, Inc.,(Nasdaq: CLRT ), a premier technology and services resource ... fourth quarter and year ended December 31, 2007.,Revenue from continuing operations ...
... -- Conference Call on Monday, March 31, ... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... months and twelve months ended December 31,2007., Highlights ... million, up 118% year-over-year -- Record full year ...
... Eisai Co.,Ltd. and its U.S. subsidiary Eisai ... District Court for the District of New,Jersey has ... motion for a,preliminary injunction in its patent infringement ... (collectively,"Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride,tablets)., ...
Cached Biology Technology:Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 3
(Date:4/15/2014)... (April 15, 2014) The American Association of ... winners. All awards will be presented during the ... Marriott Hotel on Tuesday, April 29th at 7:30 p.m. ... , The 2014 award winners are: ... Laitman, PhD, of the Icahn School of Medicine at ...
(Date:4/15/2014)... are many viral diseases in the world for which ... fever, which is spread by mosquitoes in the tropics, ... more familiar in Finland and is easily spread by ... children and the elderly. , Researchers at Aalto University ... in preliminary tests to prevent the spread of one ...
(Date:4/15/2014)... of cuttlefish, squid and octopus has uncovered details ... how they may help in investigating populations of ... described 10 new parasite species− dicyemid mesozoans −, ... squid and octopus). They are the very ... waters. , "Although dicyemid parasites have been ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Bizarre parasite may provide cuttlefish clues 2
... 2012) Researchers from the University of Minnesota and Washington ... grain products in the United States may have an impact ... published online today in the journal Pediatrics , shows ... to increase, and also finds a notable decrease in two ...
... what makes one particular strain of methicillin-resistant Staphylococcus aureus ... as the one that makes it resistant to vancomycin, ... They report their findings in mBio , the ... on Tuesday May 22. "MRSA strains are leading ...
... Emerita, Stanford University School of Medicine, Stanford, California, has been ... for her years of volunteer service to ASM. "For as ... microbiology, Baron has been the heart and soul of my ... and Development, North America, for bioMrieux, Inc., Durham, NC. ...
Cached Biology News:Folic acid food enrichment potentially protective against childhood cancers 2How one strain of MRSA becomes resistant to last-line antibiotic 2The American Society for Microbiology honors Ellen Jo Baron 2The American Society for Microbiology honors Ellen Jo Baron 3
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: